Detalhe da pesquisa
1.
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.
Future Oncol
; 14(21): 2115-2129, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29595064
2.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Lancet Oncol
; 18(2): 230-240, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28089635